SLC5A2 and atherosclerosis: Since the landmark EMPA-REG OUTCOME trial in 2015 [10], several randomized clinical trials with sodium-glucose cotransporter-2 (SGLT2) inhibitors confirmed the marked reduction in risks for ASCVD, heart failure, and kidney dysfunction in patients with T2D and even improved cardiorenal outcomes in patients without T2D [11–17].